Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ambroxol is a small molecule mucolytic and secretolytic agent used primarily for airway secretion clearance therapy in respiratory diseases associated with viscid or excessive mucus. It acts by stimulating the synthesis and release of surfactant from type II pneumocytes, reducing mucus viscosity and promoting mucociliary transport. Ambroxol also enhances ciliary activity through calcium-mediated signaling pathways, increases bicarbonate import to raise cellular pH, and stimulates chloride ion release via activation of anoctamine 1 (ANO1), further improving mucus clearance. Additionally, it has local anesthetic properties that provide pain relief in acute sore throat and may exert analgesic effects by suppressing C-fiber function. Ambroxol is available in various formulations including tablets, syrups, pastilles, inhalation solutions, drops, ampules, and effervescent tablets[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ambroxol.